Robinson D S, Johnson G A, Nies A, Corcella J, Cooper T B, Albright D, Howard D
J Clin Psychopharmacol. 1983 Oct;3(5):282-7.
Plasma norepinephrine, epinephrine, and 3,4-dihydroxyphenylglycol levels were measured in depressed outpatients treated in a double-blind controlled clinical trial with 150 mg/day of amitriptyline or 60 mg/day of phenelzine for 6 weeks. Both antidepressant drug treatments were associated with a significant decline in plasma dihydroxyphenylglycol concentrations, which was more pronounced with phenelzine. Plasma norepinephrine levels also declined during phenelzine but not amitriptyline treatment, and the posttreatment values correlated with clinical improvement with the monoamine oxidase inhibiting drug. Reductions in norepinephrine and dihydroxyphenylglycol correlated highly with the degree of platelet monoamine oxidase inhibition. Mechanisms of these antidepressant drug effects on amine metabolism and their implications are discussed.
在一项双盲对照临床试验中，对150毫克/天阿米替林或60毫克/天苯乙肼治疗6周的门诊抑郁症患者测量了血浆去甲肾上腺素、肾上腺素和3,4 - 二羟基苯乙二醇水平。两种抗抑郁药物治疗均与血浆二羟基苯乙二醇浓度显著下降相关，苯乙肼治疗时这种下降更为明显。在苯乙肼治疗期间血浆去甲肾上腺素水平也下降，但阿米替林治疗时未下降，且治疗后值与单胺氧化酶抑制药物的临床改善相关。去甲肾上腺素和二羟基苯乙二醇的降低与血小板单胺氧化酶抑制程度高度相关。讨论了这些抗抑郁药物对胺代谢的作用机制及其意义。
